Merck & Company (6MK) Stock Forecast & Price Target

Compare

68 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

6MK Analyst Ratings

Moderate Buy

9 Buy

5 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Merck

& Company

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

6MK Stock 12 Month Forecast

Average Price Target

€98.84

▲(10.93% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Merck & Company in the last 3 months. The average price target is €98.84 with a high forecast of €118.05 and a low forecast of €80.68. The average price target represents a 10.93% change from the last price of €89.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"63":"€63","77":"€77","91":"€91","105":"€105","119":"€119"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":118.04991722,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€118.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":98.8392040724,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€98.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80.6815981,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€80.68</span>\n  </div></div>","useHTML":true}}],"tickPositions":[63,77,91,105,119],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,88.051,90.35860901692308,92.66621803384615,94.97382705076923,97.28143606769231,99.58904508461538,101.89665410153846,104.20426311846154,106.5118721353846,108.81948115230769,111.12709016923077,113.43469918615384,115.74230820307692,{"y":118.04991722,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,88.051,88.88086185172308,89.71072370344615,90.54058555516923,91.37044740689231,92.20030925861539,93.03017111033846,93.86003296206154,94.68989481378462,95.51975666550769,96.34961851723077,97.17948036895385,98.00934222067691,{"y":98.8392040724,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,88.051,87.48412293076923,86.91724586153846,86.35036879230769,85.78349172307692,85.21661465384615,84.64973758461538,84.08286051538462,83.51598344615385,82.94910637692308,82.38222930769231,81.81535223846154,81.24847516923077,{"y":80.6815981,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":91.99,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.957,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.342,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.633,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.729,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.562,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.645,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.877,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.707,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.177,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.051,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€118.05

Average Price Target€98.84

Lowest Price Target€80.68

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tycho Peterson

Jefferies

€118.05

Buy

32.49%

Upside

Reiterated

12/19/25

Jefferies Keeps Their Buy Rating on Merck & Company (MRK)

Courtney Breen

Bernstein

Hold

―

Assigned

12/19/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amicus (NASDAQ: FOLD), Merck & Company (NYSE: MRK) and Cytokinetics (NASDAQ: CYTK)

Louise Chen

Scotiabank

€101.91

Buy

14.38%

Upside

Reiterated

12/19/25

Merck & Company (MRK) Gets a Buy from Scotiabank

Evan Seigerman

BMO Capital

€69.64→€110.4

Buy

23.91%

Upside

Upgraded

12/18/25

Merck: Undervalued Buy with Robust Pipeline and Diversified Post‑Keytruda Revenue Strategy

Jason Gerberry

Bank of America Securities

€101.91

Buy

14.38%

Upside

Reiterated

12/15/25

Merck & Company: Strong Growth Potential Amidst Robust Pipeline and Strategic Product Launches

Daina Graybosch

Leerink Partners

€90.87→€96.81

Buy

8.66%

Upside

Reiterated

12/15/25

Merck & Company: Strategic Diversification and Upcoming Catalysts Bolster Buy Rating

Terence Flynn

Morgan Stanley

€84.92→€86.62

Hold

-2.78%

Downside

Reiterated

12/12/25

Morgan Stanley Remains a Hold on Merck & Company (MRK)

Rajesh Kumar

HSBC

€84.92→€101.91

Buy

14.38%

Upside

Reiterated

12/10/25

Merck price target raised to $120 from $100 at HSBCMerck price target raised to $120 from $100 at HSBC

Vamil Divan

Guggenheim

€88.32→€103.61

Buy

16.28%

Upside

Reiterated

12/05/25

Merck price target raised to $122 from $104 at GuggenheimMerck price target raised to $122 from $104 at Guggenheim

Asad Haider

Goldman Sachs

€78.13→€101.91

Buy

14.38%

Upside

Reiterated

12/02/25

Merck price target raised to $120 from $92 at Goldman SachsMerck price target raised to $120 from $92 at Goldman Sachs

Mohit Bansal

Wells Fargo

€76.43→€106.16

Buy

19.14%

Upside

Upgraded

11/24/25

Merck upgraded to Overweight from Equal Weight at Wells FargoMerck upgraded to Overweight from Equal Weight at Wells Fargo

Geoff Meacham

Citi

€80.68

Hold

-9.45%

Downside

Reiterated

11/20/25

Citi Sticks to Their Hold Rating for Merck & Company (MRK)

Luisa Hector

Berenberg Bank

€76.43→€80.68

Hold

-9.45%

Downside

Reiterated

11/19/25

Berenberg Bank Sticks to Their Hold Rating for Merck & Company (MRK)

Unknown Analyst

Deutsche Bank

Not Ranked

Deutsche Bank

€94.27

Hold

5.80%

Upside

Reiterated

11/18/25

Merck & Company (MRK) Gets a Hold from Deutsche Bank

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

€84.92→€76.43

Hold

-14.22%

Downside

Downgraded

09/17/25

Merck & Company (MRK) was downgraded to a Hold Rating at Roth MKM

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tycho Peterson

Jefferies

€118.05

Buy

32.49%

Upside

Reiterated

12/19/25

Jefferies Keeps Their Buy Rating on Merck & Company (MRK)

Courtney Breen

Bernstein

Hold

―

Assigned

12/19/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amicus (NASDAQ: FOLD), Merck & Company (NYSE: MRK) and Cytokinetics (NASDAQ: CYTK)

Louise Chen

Scotiabank

€101.91

Buy

14.38%

Upside

Reiterated

12/19/25

Merck & Company (MRK) Gets a Buy from Scotiabank

Evan Seigerman

BMO Capital

€69.64→€110.4

Buy

23.91%

Upside

Upgraded

12/18/25

Merck: Undervalued Buy with Robust Pipeline and Diversified Post‑Keytruda Revenue Strategy

Jason Gerberry

Bank of America Securities

€101.91

Buy

14.38%

Upside

Reiterated

12/15/25

Merck & Company: Strong Growth Potential Amidst Robust Pipeline and Strategic Product Launches

Daina Graybosch

Leerink Partners

€90.87→€96.81

Buy

8.66%

Upside

Reiterated

12/15/25

Merck & Company: Strategic Diversification and Upcoming Catalysts Bolster Buy Rating

Terence Flynn

Morgan Stanley

€84.92→€86.62

Hold

-2.78%

Downside

Reiterated

12/12/25

Morgan Stanley Remains a Hold on Merck & Company (MRK)

Rajesh Kumar

HSBC

€84.92→€101.91

Buy

14.38%

Upside

Reiterated

12/10/25

Merck price target raised to $120 from $100 at HSBCMerck price target raised to $120 from $100 at HSBC

Vamil Divan

Guggenheim

€88.32→€103.61

Buy

16.28%

Upside

Reiterated

12/05/25

Merck price target raised to $122 from $104 at GuggenheimMerck price target raised to $122 from $104 at Guggenheim

Asad Haider

Goldman Sachs

€78.13→€101.91

Buy

14.38%

Upside

Reiterated

12/02/25

Merck price target raised to $120 from $92 at Goldman SachsMerck price target raised to $120 from $92 at Goldman Sachs

Mohit Bansal

Wells Fargo

€76.43→€106.16

Buy

19.14%

Upside

Upgraded

11/24/25

Merck upgraded to Overweight from Equal Weight at Wells FargoMerck upgraded to Overweight from Equal Weight at Wells Fargo

Geoff Meacham

Citi

€80.68

Hold

-9.45%

Downside

Reiterated

11/20/25

Citi Sticks to Their Hold Rating for Merck & Company (MRK)

Luisa Hector

Berenberg Bank

€76.43→€80.68

Hold

-9.45%

Downside

Reiterated

11/19/25

Berenberg Bank Sticks to Their Hold Rating for Merck & Company (MRK)

Unknown Analyst

Deutsche Bank

Not Ranked

Deutsche Bank

€94.27

Hold

5.80%

Upside

Reiterated

11/18/25

Merck & Company (MRK) Gets a Hold from Deutsche Bank

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

€84.92→€76.43

Hold

-14.22%

Downside

Downgraded

09/17/25

Merck & Company (MRK) was downgraded to a Hold Rating at Roth MKM

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merck & Company

1 Month

xxx

Success Rate

17/26 ratings generated profit

Average Return

+1.72%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.38% of your transactions generating a profit, with an average return of +1.72% per trade.

3 Months

xxx

Success Rate

18/26 ratings generated profit

Average Return

+3.48%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +3.48% per trade.

1 Year

Daina GrayboschLeerink Partners

Success Rate

36/52 ratings generated profit

Average Return

+9.63%

reiterated a buy rating 12 days ago

Copying Daina Graybosch's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +9.63% per trade.

2 Years

xxx

Success Rate

18/19 ratings generated profit

Average Return

+17.98%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 94.74% of your transactions generating a profit, with an average return of +17.98% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6MK Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 6MK has received 25 Buy Ratings, 17 Hold Ratings, and 0 Sell Ratings. 6MK average Analyst price target in the past 3 months is 98.84.

Each month's total comprises the sum of three months' worth of ratings.

6MK Financial Forecast

6MK Earnings Forecast

Next quarter’s earnings estimate for 6MK is €1.74 with a range of €1.68 to €1.87. The previous quarter’s EPS was €2.19. 6MK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 6MK has Performed in-line its overall industry.

6MK Sales Forecast

Next quarter’s sales forecast for 6MK is €13.75B with a range of €13.61B to €13.90B. The previous quarter’s sales results were €14.58B. 6MK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 6MK has Performed in-line its overall industry.

6MK Stock Forecast FAQ

What is DE:6MK’s average 12-month price target, according to analysts?

Based on analyst ratings, Merck & Company’s 12-month average price target is 98.84.

What is DE:6MK’s upside potential, based on the analysts’ average price target?

Merck & Company has 10.93% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Merck & Company a Buy, Sell or Hold?

Merck & Company has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 5 hold ratings and 0 sell ratings.

What is Merck & Company’s share price target?

The average share price target for Merck & Company is 98.84. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €118.05 ,and the lowest forecast is €80.68. The average share price target represents 10.93% Increase from the current price of €89.1.

What do analysts say about Merck & Company?

Merck & Company’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Merck & Company?

To buy shares of DE:6MK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Merck & Company (6MK) Stock Forecast & Price Target

6MK Analyst Ratings

6MK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Merck & Company

6MK Analyst Recommendation Trends

6MK Financial Forecast

6MK Earnings Forecast

6MK Sales Forecast

6MK Stock Forecast FAQ

Detailed List of Analyst Forecasts